Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
Takeda Pharmaceutical said on June 6 that it will pull the plug on a multinational PIII clinical study of its multiple myeloma drug Ninlaro (ixazomib) in patients with relapsed/refractory systemic light-chain (AL) amyloidosis. The PIII TOURMALINE-AL1 study evaluated the improvement…
To read the full story
Related Article
BUSINESS
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
- Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
February 26, 2026
- Towa Wins Pediatric Autism Use for Abilify Generic
February 26, 2026
- Jardiance Tops Five Promotion Channels in January: Intage
February 26, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…